NEW CYTOTOXIC DRUGS AND TARGETS IN ONCOLOGY

被引：4
作者：
BEIJNEN, JH
机构：
[1] Slotervaart Hospital/Netherlands Cancer Institute, EC Amsterdam, 1066
来源：
PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION | 1992年 / 14卷 / 4A期
关键词：
BRYOSTATIN-1; NEW CYTOTOXIC DRUGS; SIGNAL TRANSDUCTION; TAXOL; TOPOISOMERASE INHIBITORS; TOPOTECAN; TUBULIN POISONS;
D O I：
10.1007/BF01962548
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
New agents in the preclinical and early clinical pipeline (phases I and II) are described and some of the problems associated with their development are reviewed. The article focuses on tubulin poisons such as taxol, topoisomerase inhibitors, such as topotecan, and drugs such as bryostatin 1 and miltefosin, which interfere with specific signal transduction pathways involved in malignant cell growth.
引用
收藏
页码：258 / 267
页数：10
相关论文
共 74 条
  • [1] AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
  • [2] ARISTOFF PA, 1989, 6TH NCI EORTC S NEW
  • [3] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF THE NEW ANTITUMOR DRUG SK-AND-F 104864-A (NSC 609699) IN PLASMA
    BEIJNEN, JH
    SMITH, BR
    KEIJER, WJ
    VANGIJN, R
    HUININK, WWT
    VLASVELD, LT
    RODENHUIS, S
    UNDERBERG, WJM
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) : 789 - 794
  • [4] BEIJNEN JH, 1990, REPORT FORMULATION U
  • [5] BEILING P, 1991, P AN M AM SOC CLIN, V10, P308
  • [6] BERDEL WE, 1990, ONKOLOGIE, V13, P245
  • [7] CLINICAL PHASE-I PILOT-STUDY OF THE ALKYL LYSOPHOSPHOLIPID DERIVATIVE ET-18-OCH3
    BERDEL, WE
    FINK, U
    RASTETTER, J
    [J]. LIPIDS, 1987, 22 (11) : 967 - 969
  • [8] BISSERY MC, 1990, P AM ASSOC CANC RES, V31, P447
  • [9] BLUMBERG PM, 1988, CANCER RES, V48, P1
  • [10] DISTAMYCINS INHIBIT THE BINDING OF OTF-1 AND NFE-1 TRANSFACTORS TO THEIR CONSERVED DNA ELEMENTS
    BROGGINI, M
    PONTI, M
    OTTOLENGHI, S
    DINCALCI, M
    MONGELLI, N
    MANTOVANI, R
    [J]. NUCLEIC ACIDS RESEARCH, 1989, 17 (03) : 1051 - 1059
12345678